These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26496802)

  • 1. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
    Shen W; Taylor B; Jin Q; Nguyen-Tran V; Meeusen S; Zhang YQ; Kamireddy A; Swafford A; Powers AF; Walker J; Lamb J; Bursalaya B; DiDonato M; Harb G; Qiu M; Filippi CM; Deaton L; Turk CN; Suarez-Pinzon WL; Liu Y; Hao X; Mo T; Yan S; Li J; Herman AE; Hering BJ; Wu T; Martin Seidel H; McNamara P; Glynne R; Laffitte B
    Nat Commun; 2015 Oct; 6():8372. PubMed ID: 26496802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
    Rachdi L; Kariyawasam D; Guez F; Aïello V; Arbonés ML; Janel N; Delabar JM; Polak M; Scharfmann R
    Diabetologia; 2014 May; 57(5):960-9. PubMed ID: 24477974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance.
    Rachdi L; Kariyawasam D; Aïello V; Herault Y; Janel N; Delabar JM; Polak M; Scharfmann R
    Cell Cycle; 2014; 13(14):2221-9. PubMed ID: 24870561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
    Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
    Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
    Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
    Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
    Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation.
    Liu Z; Tanabe K; Bernal-Mizrachi E; Permutt MA
    Diabetologia; 2008 Apr; 51(4):623-31. PubMed ID: 18219478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
    Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
    J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel factors modulating human β-cell proliferation.
    Shirakawa J; Kulkarni RN
    Diabetes Obes Metab; 2016 Sep; 18 Suppl 1(Suppl 1):71-7. PubMed ID: 27615134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal growth and regeneration of beta-cells are regulated by the Wnt/beta-catenin signaling in normal and diabetic rats.
    Figeac F; Uzan B; Faro M; Chelali N; Portha B; Movassat J
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E245-56. PubMed ID: 19920216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYRK1A aggravates β cell dysfunction and apoptosis by promoting the phosphorylation and degradation of IRS2.
    Lu M; Ma L; Shan P; Liu A; Yu X; Jiang W; Wang X; Zhao X; Ye X; Wang T
    Exp Gerontol; 2019 Oct; 125():110659. PubMed ID: 31306739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
    Liu YA; Jin Q; Zou Y; Ding Q; Yan S; Wang Z; Hao X; Nguyen B; Zhang X; Pan J; Mo T; Jacobsen K; Lam T; Wu TY; Petrassi HM; Bursulaya B; DiDonato M; Gordon WP; Liu B; Baaten J; Hill R; Nguyen-Tran V; Qiu M; Zhang YQ; Kamireddy A; Espinola S; Deaton L; Ha S; Harb G; Jia Y; Li J; Shen W; Schumacher AM; Colman K; Glynne R; Pan S; McNamara P; Laffitte B; Meeusen S; Molteni V; Loren J
    J Med Chem; 2020 Mar; 63(6):2958-2973. PubMed ID: 32077280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
    Ackeifi C; Wang P; Karakose E; Manning Fox JE; González BJ; Liu H; Wilson J; Swartz E; Berrouet C; Li Y; Kumar K; MacDonald PE; Sanchez R; Thorens B; DeVita R; Homann D; Egli D; Scott DK; Garcia-Ocaña A; Stewart AF
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
    Wang P; Alvarez-Perez JC; Felsenfeld DP; Liu H; Sivendran S; Bender A; Kumar A; Sanchez R; Scott DK; Garcia-Ocaña A; Stewart AF
    Nat Med; 2015 Apr; 21(4):383-8. PubMed ID: 25751815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of pancreatic beta-cell mass and proliferation by SOCS-3.
    Lindberg K; Rønn SG; Tornehave D; Richter H; Hansen JA; Rømer J; Jackerott M; Billestrup N
    J Mol Endocrinol; 2005 Oct; 35(2):231-43. PubMed ID: 16216905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
    Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T
    Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.